Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Florence Raynaud Stan Kaye Gerhardt Attard |
| Publication date | July 21, 2008 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |